ImmuPharma (LON:IMM) Trading Down 9.9% - Here's Why

Key Points

• ImmuPharma's stock price fell by 9.9% on Thursday, reaching a low of GBX 10.58 ($0.14) from a previous close of GBX 12.10 ($0.16).
• The company reported a negative EPS of GBX (0.38) for the last quarter, and analysts predict an annual EPS of -339.0000022.
• ImmuPharma specializes in peptide-based therapeutics, focusing on autoimmune diseases with its lead program, Lupuzor™, targeting Lupus and other similar conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 9.9% during trading on Thursday . The company traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). Approximately 14,800,078 shares were traded during mid-day trading, an increase of 72% from the average daily volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Stock Down 8.3%

The firm's 50 day simple moving average is GBX 4.84 and its two-hundred day simple moving average is GBX 3.44. The stock has a market capitalization of £50.87 million, a P/E ratio of -1,143.82 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.